Morepen Laboratories Limited
Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.
What Morepen files
- Others58
- Important37
- Updates32
- Investor Meet9
- Board Meeting8
- PPTs6
Business Update First Phase of Manufacturing Capacity Expansion Completed Ahead of Schedule
Morepen Labs invested ₹20 Cr in its wholly-owned pharma subsidiary, Morepen RX Ltd, via a rights issue. This capital infusion strengthens MRX's base and supports its branded Rx products business. MRX reported a FY26 turnover of ₹54.49 Cr.
Morepen Labs reported robust Q1 financial results: Consolidated revenue surged to ₹570.13 Cr and profit to ₹56.35 Cr. The board extended the medical devices business hive-off timeline and proposed re-appointing Sushil Suri as CMD for three years.
Morepen Labs hit record Q1'FY27 revenue of Rs 575.31 Cr (+34% YoY), EBITDA Rs 87.72 Cr (+207%), and PAT Rs 56.35 Cr (+394%). Its Rs 825 Cr CDMO mandate commenced full commercialization, with Rs 58 Cr dispatches. Strong API and Medical Devices growth supported performance.
Morepen Labs' wholly owned subsidiary, Morepen Labs - FZCO, is now Morepen Labs FZE. This change follows its migration to Jebel Ali Free Zone (JAFZA) for operational reasons.